Comparison of prostaglandin analogue, beta-blockers and prostaglandin analogue/beta-blockers 239 1 3
SummaryPurpose To compare intraocular pressure (IOP)-lowering efficacy of prostaglandin analogue, beta-blocker and prostaglandin analogue/beta-blocker fixed combination ophthalmic solution in patients with open-angle glaucoma.Methods In this prospective, multicentre, randomized clinical trial, 120 qualifying patients received prostaglandin/beta-blocker once daily (n = 40), prostaglandin analogue once daily in the evening (n = 40) or beta-blocker twice daily (n = 40). Efficacy was compared across treatment groups over 1 year.Results Mean IOP at the first visit in the prostaglandin group was 26.6 mmHg (SD ± 2.0 mmHg), in betablockers group was 25.9 mmHg (SD ± 1.7 mmHg) and in prostaglandin/beta-blockers group was 26.3 mmHg (SD ± 2.0 mmHg). Mean IOP at the seventh visit (after 1 year) in the prostaglandin group was 19.8 mmHg (SD ± 1.3 mmHg), in beta-blockers group was 21.3 mmHg (SD ± 1.2 mmHg) and in prostaglandin/beta-blockers group was 18.4 mmHg (SD ± 1.3 mmHg; range: 16.0-21.0 mmHg). There was no statistically significant difference of IOP in both eyes on seventh visit by groups (KW = 113.0, p < 0.0001).Conclusions Over 1 year of treatment, prostaglandin analogue/beta-blockers produced clinically relevant IOP reductions in patients with open-angle glaucoma that were greater than those produced by either prostaglandin analogue or beta-blockers alone. Prostaglandin analogue/beta-blocker provides both more effective IOP reduction than its components and the benefits of oncedaily dosing.
Aim: The purpose of this study was to compare measurements of CCT in emmetropia and patient with refractive anomalies. Methods: We represent a retrospective research which was conducted at the University Clinical Center of Kosovo (UCCK). In this study were included 80 patients, divided into two groups: test and a control group. Mean age was (M = 25.90, DS = 7.16), men (N = 41% or 51.3%) and women (N = 39% or 48%). Results: Results show that there were no differences in the CCT, Hyperopic (M = 545.21 DS = 52.24), Myopic (M = 547.90 DS = 47.93) and Emmetropic (M = 550.75 DS = 41.29). After measuring of the longitudinal axis and analyzing the data by means of Anova test, it appeared to be a significant difference between the analyzed groups, Hyperopic (M = 21.99, DS = 1.27), Myopics (M = 23.21, DS = 1.24), Emmetropic (M = 22.36, DS = 0.81). Results also revealed that there is correlation between the CCT and IOP, where increase CCT decreases IOP and vice versa (r = −0.26, p = 0.01). Conclusion: The results have shown that CCT is thinner in myopic but does not show correlation with hypermetropic and emmetropic. While during the measurement of central corneal thickness and eye tension it is found that there is a negative correlation between them. Keratometry has a negative correlation with CCT. While there was no correlation between CCT and age. Given the role of CCT in interpreting IOP values, it is recommended to perform a systematic CCT measurement in routine clinical practice, which would assist in the diagnosis of ocular hypertension.
Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety of travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed combination ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Methods: In this prospective, multicentre clinical trial, 62 patients received travoprost 0.004% (n = 31) or travoprost 0.004% and beta-blocker 0.5% fixed combination (n = 31). Efficacy and safety were compared across treatment groups over 2 years. IOP reduction and adverse events were examined at 3, 6, 12 and 24 months for each group. Results: Mean IOP at the first visit in the travoprost 0.004% group was 26.4 (SD ± 2.1), and travoprost 0.004%/timolol 0.5% group was 26.3 (SD ± 2.1). Mean IOP after 24 months in the travoprost 0.004% group was 20.5 (SD ± 1.5) and travoprost 0.004%/timolol 0.5% group was 18.5 (SD ± 1.5). There were statistically significant differences in IOP in both eyes after third visit (after 1 year) and fourth visit (after 2 years). Conclusion: After 2 year of treatment, travoprost 0.004%/timolol 0.5% produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by travoprost 0.004% alone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.